Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

NextGen Healthcare Information Systems, LLC, a fully-owned subsidiary of Quality Systems, Inc. (QSII - Analyst Report), recently declared its receipt of the ONC HIT certification for its latest offering. This positive piece of news should leverage investor confidence in the stock. On a year-to-date basis, the company’s share price surged 31%.

On Sep 18, NextGen Inpatient Clinicals version 2.6 was certified as a Complete Electronic Health Record (Complete EHR) by the Certification Commission for Health Information Technology (CCHIT), an ONC Authorized Certification Body (ONC-ACB). The device is now compliant with the ONC 2014 Edition criteria, which supports both Stage 1 and 2 Meaningful Use (MU) measures.

The EHR technology certification is an important milestone for QSII, which renders a competitive edge to the company’s product portfolio. Compliance with MU Stage 2 was an essential benchmark that was required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

The NextGen Inpatient Clinicals is a proven solution at critical access and community hospitals in the U.S. This comprehensive clinical system includes computer physician order entry (CPOE), clinical decision support, order management, advanced reporting, clinical data repository and additional features.

Earlier, in Sep, the NextGen Healthcare Information Systems subsidiary hit the headlines by presenting a clinical decision support (CDS) tool that will help healthcare providers achieve evidence-based clinical knowledge much more easily. NextGen’s client Willamette Valley Providers (WVP) has agreed to take the program live with a commercial EHR.

Quality Systems presently has a Zacks Rank #3 (Hold). While we remain on the sidelines regarding QSII, other medical stocks that are worth considering include Cardinal Health, Inc. (CAH - Analyst Report), Bio-Rad Laboratories, Inc. (BIO - Snapshot Report) and STRAUMANN HLD N AKT (SAUHF). All these stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.38 +14.99%
ATLAS FINANC AFH 14.65 +2.85%
ZIOPHARM ONC ZIOP 3.44 +2.08%
ALLIANCE FIB AFOP 17.66 +1.96%
FEDERATED NA FNHC 20.26 +1.96%